Regulatory approval

Published by the Health Service Executive. Approved

Neoadjuvant treatment of adult patients with HER2-positive locally advanced, inflammatory or early breast cancer at high risk of recurrence.

This is written in the approval document.

Reimbursement

Incomplete Reimbursement

Pertuzumab / Trastuzumab (Phesgo) - ODMS 2022-12-20; Carboplatin and Docetaxel - N/A

Citation

DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo)(TCHP) Therapy, 2024, version number 3, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6447/789_v3_TCHP_Phesgo.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Pertuzumab, Trastuzumab